Sonnet Biotherapeutics Holdings Stock One Year Return
| SONN Stock | USD 2.79 0.02 0.71% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Sonnet Biotherapeutics' long-term financial health and intrinsic value.
Sonnet | One Year Return | Build AI portfolio with Sonnet Stock |
Sonnet Biotherapeutics Holdings Company One Year Return Analysis
Sonnet Biotherapeutics' One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Sonnet One Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Sonnet Biotherapeutics is extremely important. It helps to project a fair market value of Sonnet Stock properly, considering its historical fundamentals such as One Year Return. Since Sonnet Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sonnet Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sonnet Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
| Competition |
Sonnet Return On Tangible Assets
Return On Tangible Assets |
|
Based on the recorded statements, Sonnet Biotherapeutics Holdings has an One Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Sonnet Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sonnet Biotherapeutics from analyzing Sonnet Biotherapeutics' financial statements. These drivers represent accounts that assess Sonnet Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sonnet Biotherapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 48.4M | 14.9M | 6.4M | 3.0M | 4.4M | 8.6M | |
| Enterprise Value | 41.4M | (12.6M) | 3.6M | 904.0K | 4.4M | 17.9M |
Sonnet Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sonnet Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sonnet Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Sonnet Fundamentals
| Return On Equity | -7.15 | ||||
| Return On Asset | -1.77 | ||||
| Operating Margin | (13.78) % | ||||
| Current Valuation | 15.63 M | ||||
| Shares Outstanding | 6.26 M | ||||
| Shares Owned By Insiders | 1.76 % | ||||
| Shares Owned By Institutions | 2.64 % | ||||
| Number Of Shares Shorted | 1.14 M | ||||
| Price To Book | 26.58 X | ||||
| Price To Sales | 17.60 X | ||||
| Revenue | 18.63 K | ||||
| Gross Profit | (69.01 K) | ||||
| EBITDA | (11.77 M) | ||||
| Net Income | (7.44 M) | ||||
| Cash And Equivalents | 5.22 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 130.86 K | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 1.10 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (8.61 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (12.07) X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 17.6 M | ||||
| Total Asset | 2.77 M | ||||
| Retained Earnings | (117.68 M) | ||||
| Working Capital | (1.09 M) | ||||
| Net Asset | 2.77 M |
About Sonnet Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sonnet Biotherapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonnet Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonnet Biotherapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock: Check out Sonnet Biotherapeutics Piotroski F Score and Sonnet Biotherapeutics Altman Z Score analysis. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.07) | Revenue Per Share | Quarterly Revenue Growth 52.688 | Return On Assets | Return On Equity |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.